Table 2.
Routine CSF follow-up results.
| Time since DIAVIS T-cell therapy initiation (weeks) | 0 | 4 | 14 |
|---|---|---|---|
| CSF cells/µl | 1 | 1 | 3 |
| CSF lactate (mmol/l) | 1.76 | 1.94 | 1.98 |
| CSF protein (mg/l) | 340 | 310 | 440 |
| Oligoclonal bands | Type 3 | Type 3 | Type 3 |
| Albumin quotient | 3.81 | 5.17 | 6.37 |
| Intrathecal IgM synthesis (%) | 47 | 27.4 | 0 |
| Intrathecal IgG synthesis (%) | 61.1 | 47.9 | 38.6 |
| Intrathecal IgA synthesis (%) | 0 | 26.8 | 0 |
Follow-up routine CSF parameters from the time of therapy initiation are shown here. No new inflammatory process, such as pleocytosis indicative of PML-IRIS, was observed.
CSF, cerebrospinal fluid; DIAVIS T-cells, directly isolated allogeneic virus-specific T-cells; Ig, immunoglobulin; IRIS, Immune Reconstitution Inflammatory Syndrome; PML, progressive multifocal leukoencephalopathy.